First-in-class compound proves safe, tolerable in preventing blood clots

Mar 12, 2009

A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI).

Results of the Phase II study of the , known as SCH 530348, appear online in the journal The Lancet and will appear in the publication's Mar. 14 issue. An international, Phase III study is already under way.

Thrombin is a protein in the blood that performs two key functions in clot formation: It activates platelets, particles that clump together to form the scaffolding of a clot, and it helps produce fibrin, a protein necessary in repairing damaged tissue.

"One of the intriguing things about this new investigational compound is that it blocks the that activates platelet formation yet preserves the beneficial activity of fibrin formation," said Richard Becker, M.D., a cardiologist at DCRI and the lead author of the study. "And the data to date indicated the compound does this even when are taking aspirin and clopidogrel."

Blood clots are a big issue for patients facing percutaneous (PCI) the process of clearing with a balloon and then propping them open with stents. Patients who undergo PCI are usually prescribed anti-clotting agents like aspirin or clopidgrel (Plavix). Becker said while those drugs are effective, they can sometimes lead to , and with current therapy, the rate of additional cardiovascular events remains quite high. "So there is a very aggressive search going on for better and safer agents," he said.

In the current study, researchers randomly assigned 1030 patients 45 years or older scheduled to undergo non-urgent PCI or with planned PCI to a group that would receive one of three escalating doses of SCH 530348 (10 mg, 20 mg or 40 mg), or to a control group, which took a placebo. Both researchers and patients were both blinded to who was taking which drug.

Aspirin and clopidogrel were not prescribed as part of the study - investigators followed standard practice at each study site and found that 95 percent of the patients were given both aspirin and clopidogrel.

Two hundred and twenty-seven patients were assigned to placebo; 773 took the experimental drug. Researchers measured responses across all four groups with special focus on the primary clinical endpoint, which was the amount of bleeding according to the thrombolysis in myocardial infarction (TIMI) scale.

They found that SCH 530348 was generally tolerable at all dosing levels and did not increase bleeding, even when taken along with aspirin and clopidogrel. Bleeding occurred in 2 percent of 129, 3 percent of 120, and 4 percent of 173 patients in the 10 mg, 20 mg, and 40 mg drug groups, respectively; compared with 3 percent of the 151 patients in the placebo group (p = .5786).

Patients were also randomized to a daily maintenance dose of the drug (.5 mg, 1 mg, or 2.5 mg). Investigators found that bleeding occurred in 2 percent of 136, 4 percent of 139 and 3 percent of 138 patients in those groups, respectively, compared with 2 percent in the placebo group (p = .7561).

"The uncoupling of benefit and bleeding risk among patients with acute coronary syndromes is an important objective in drug development," Becker said. "We will need to see if Phase III clinical trials can confirm these findings."

Source: Duke University Medical Center

Explore further: Missing protein restored in patients with muscular dystrophy

add to favorites email to friend print save as pdf

Related Stories

Baby aspirin better for your health, study says

May 08, 2007

Nearly a quarter of a million Americans each year may be hospitalized with bleeding complications caused by needlessly taking a daily dose of an adult-sized aspirin rather than a baby aspirin to prevent a heart attack or ...

Aspirin in Heart Attack Prevention: How Much, How Long?

Jan 15, 2008

A low dose of aspirin appears to be just as effective as a higher dose in preventing a heart attack, stroke or death among patients with stable cardiovascular disease, say researchers at Duke University Medical Center.

Recommended for you

Student seeks to improve pneumonia vaccines

13 hours ago

Almost a million Americans fall ill with pneumonia each year. Nearly half of these cases require hospitalization, and 5-7 percent are fatal. Current vaccines provide protection against some strains of the ...

Seabed solution for cold sores

14 hours ago

The blue blood of abalone, a seabed delicacy could be used to combat common cold sores and related herpes virus following breakthrough research at the University of Sydney.

Better living through mitochondrial derived vesicles

Aug 19, 2014

(Medical Xpress)—As principal transformers of bacteria, organelles, synapses, and cells, vesicles might be said to be the stuff of life. One need look no further than the rapid rise to prominence of The ...

Zebrafish help to unravel Alzheimer's disease

Aug 19, 2014

New fundamental knowledge about the regulation of stem cells in the nerve tissue of zebrafish embryos results in surprising insights into neurodegenerative disease processes in the human brain. A new study by scientists at ...

User comments : 0